Q-omics provides the consensus-scored RGS11 profile across patient tissues and cancer cell-line models. RGS11 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RGS11 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, RGS11 RNA expression shows 15,842 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, BLCA, and BRCA as cancer lineages where RGS11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS11 survival associations across molecular data types. RGS11 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS11 RNA expression–survival associations across cancer types. High RGS11 expression shows unfavorable associations in UVM, UCEC and KIRC, but favorable associations in LUAD, KICH and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RGS11 RNA expression.
This table summarizes RGS11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RGS11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS11 shows lower tumor expression in BLCA, HNSC, KIRC, LUAD, LUSC and STAD. The BLCA box plot shows higher RGS11 RNA expression in normal versus tumor tissue (log2 FC = −1.205, t-test p < 0.001).
This table shows molecular features associated with RGS11 in patient tissues and cancer cell lines. In patient samples, RGS11 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
